Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

Reuven Or(Hebrew University of Jerusalem), Shimon Slavin(Hadassah Academic College), Elizabeth Naparstek(Hebrew University of Jerusalem), Arnon Nagler(Tel Aviv University), Aliza Ackerstein(Hadassah Academic College), Memet Aker(Hadassah Academic College), Igor Resnick(Hebrew University of Jerusalem), Avraham Amar(Hadassah Academic College), Simcha Samuel(Hadassah Academic College), Michael Y. Shapira(Hebrew University of Jerusalem)

Blood

December 31, 2002

10.1182/blood-2002-02-0535

Cited by 213

Related Papers

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.9k

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.8k

Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

|New England Journal of Medicine|2009|1k

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

|New England Journal of Medicine|2020|859

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

|Journal of Clinical Oncology|2013|439